We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Researchers Develop Vaccine that Protects Primates Against Ebola

Researchers Develop Vaccine that Protects Primates Against Ebola

Researchers Develop Vaccine that Protects Primates Against Ebola

Researchers Develop Vaccine that Protects Primates Against Ebola

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Researchers Develop Vaccine that Protects Primates Against Ebola"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Previous studies with primates suggest that aerosols of most biothreat agents, which are particles dispersed in the air, are infectious. Recent studies show that contact with the Ebola virus through the mucus membranes that line the respiratory tract results in infection, suggesting that airway linings may be important portals of entry for the virus. Aerosolized delivery has never before been tested for an Ebola vaccine or any other viral hemorrhagic fever vaccine.

“A needle-free, inhalable vaccine against Ebola presents certain advantages,” said lead author Michelle Meyer, UTMB postdoctoral fellow in the department of pathology. “Immunization will not require trained medical personnel.”


The study characterized the immune responsgenerated by vaccination against Ebola delivered to the respiratory tract as either an aerosol or liquid. Direct comparisons were made with an unrelated protective injectable Ebola vaccine. This included detailed comparisons between immune T cell responses in the lungs, spleen and blood. A single vaccination with the aerosol developed by the researchers protected non-human primates against the severe disease and death caused by lethal Ebola infection.

“This study demonstrates successful aerosol vaccination against a viral hemorrhagic fever for the first time,” said virologist Alex Bukreyev, UTMB professor and a senior author. “A single-dose aerosol vaccine would enable both prevention and containment of Ebola infections, in a natural outbreak setting where healthcare infrastructure is lacking or during bioterrorism and biological warfare scenarios.”

The findings of this study provide the basis for advancing this experimental vaccine to an NIH phase I clinical study. Pending approval through an Investigative New Drug Application, the aerosolized form of the vaccine will be evaluated for replication, safety and immunity development in a study in adults.